Synthetic Biologics CEO Jeff Riley Discusses ‘Gene Medicine 2.0’
Synthetic Biologics (SYN) is a biotechnology company focused on the development of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses.
Articles by MMargolis
The Technology Corner: Disruptive Technology for Prostate Cancer
In this special series we present emerging technologies which hold the promise to significantly improve the prognosis of patients diagnosed with prostate cancer, and cancer in general.
The Future of Healthcare: Part II, The Waiting Room of Tomorrow
In Part II of our expert series on the future of healthcare and The Patient, OneMedSentinel sits down with Dr. Cynthia Haines to discuss the digitization of the waiting room.
The Future of Healthcare: Part I, How the Empowered Patient Can Fix a Broken System
Dr. Cindy Haines has made it her mission to help patients navigate through the imperfect healthcare system, which she has described as “broken.”
CIN Special Report: Part II, Treatments Ready to Eradicate Pre-Cervical Cancer
Part II of the report identifies several disruptive technologies that may overcome the challenges of mainstream treatments.
CIN Special Report: Part I, Can a Dangerous Pre-Cancer Threat Be Tamed?
In response to some recent successes by several companies operating in the cervical cancer space, we are issuing a two-part special report exploring pre-cervical cancer and CIN.
Apricus Bio VP: Drug Delivery Space Is Evolving During Personalized Medicine Surge
Apricus Bio VP Edward Cox discusses the future of drug delivery technology in the rapidly expanding world of personalized medicine.
Dr. Shi of EdgeTech Law: Genome Sequencing Could Soon Enter Mainstream
In Part III of our interview with Dr. Qin Shi of Edgetech Law we visit the concept of human genome sequencing as a mainstream commodity.
Dr. Shi of EdgeTech Law: Emerging Opportunities in Life Sciences, Abroad
In Part II of our special interview series, Dr. Qin Shi of Edgetech Law discusses the emerging areas of significant unmet need in life science, and what investment opportunities may arise.
Dr. Shi of EdgeTech Law: Despite Mayo Clinic v. Prometheus “Setback,” Opportunities in Life Sciences Remain
OneMedPlace is pleased to announce a special interview series exploring current issues facing the diagnostics sector and life sciences.